Voyager Therapeutics’ (VYGR) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research report released on Thursday morning,Benzinga reports. They currently have a $30.00 target price on the stock.

Other equities research analysts also recently issued reports about the stock. Wells Fargo & Company set a $10.00 price objective on shares of Voyager Therapeutics and gave the company an “overweight” rating in a research report on Wednesday. Citigroup initiated coverage on Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target for the company. StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Voyager Therapeutics in a research note on Wednesday. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $14.86.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR opened at $4.07 on Thursday. The business’s fifty day moving average price is $4.91 and its two-hundred day moving average price is $5.86. The stock has a market cap of $222.33 million, a PE ratio of 5.73 and a beta of 0.99. Voyager Therapeutics has a one year low of $3.56 and a one year high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The company had revenue of $4.39 million for the quarter, compared to analyst estimates of $16.58 million. During the same period in the previous year, the business earned $1.25 EPS. As a group, equities research analysts predict that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Insider Activity at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the transaction, the chief operating officer now directly owns 112,328 shares in the company, valued at $634,653.20. This trade represents a 5.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have sold 10,778 shares of company stock worth $58,548. 4.53% of the stock is owned by insiders.

Institutional Trading of Voyager Therapeutics

A number of institutional investors have recently modified their holdings of VYGR. Empowered Funds LLC lifted its position in Voyager Therapeutics by 5.4% during the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock valued at $262,000 after buying an additional 2,278 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Voyager Therapeutics by 3.4% during the 4th quarter. Rhumbline Advisers now owns 71,497 shares of the company’s stock valued at $405,000 after acquiring an additional 2,354 shares in the last quarter. Wells Fargo & Company MN boosted its position in Voyager Therapeutics by 3.7% during the 4th quarter. Wells Fargo & Company MN now owns 66,718 shares of the company’s stock worth $378,000 after purchasing an additional 2,400 shares during the period. Picton Mahoney Asset Management boosted its position in Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after purchasing an additional 2,444 shares during the period. Finally, Tower Research Capital LLC TRC increased its holdings in Voyager Therapeutics by 133.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock valued at $31,000 after purchasing an additional 3,077 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.